AI Bias Analysis
4 models · Takes ~15 seconds
(MedPage Today) -- CHICAGO -- Adding an investigational TROP2-targeted antibody-drug conjugate (ADC) to first-line immunotherapy for PD-L1-positive non-small cell lung cancer (NSCLC) reduced the risk of disease progression and may have improved...
Source
MedPage Today
Opens original article in a new tab
ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of Texas Tech Health El Paso, look at the top medical...
(MedPage Today) -- Functional endometrial recovery was not a sure thing for patients who underwent fertility-sparing treatment before endometrial cancer treatment, researchers from China reported. In the retrospective cohort study, patients who...
(MedPage Today) -- I have spent 20 years working in out-of-network healthcare reimbursement. After reading the New York Times article "A $440,000 Breast Reduction? How Doctors Cash In on a Health Care Law," I felt the payer's use of the independent...
